Felzartamab  (Synonyms: MOR-202)

Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research^[1][2].

Human IgG1 lambda1

Human IgG1 lambda1, Isotype Control

Humanized

The MOR202-mediated toxic effects on multiple myeloma (MM) cell lines can be enhanced by the proteasome inhibitor bortezomib (BOR) and the immunomodulator lenalidomide (LEN)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MOR202 can reduce osteolysis dose-dependently by up to 55% at 12 mg/kg. Co-administration with 0.6 mg/kg BOR or 50 mg/kg LEN at a low dose of 3 mg/kg completely eliminates osteolysis in mice MM model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2197112-39-1

Liquid

Colorless to light yellow

[Felzartamab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 lambda

• 
  Immobilized Human CD38 Protein (ECD, His Tag) can bind Felzartamab. The EC₅₀ for this effect is 2.30 ng/mL.

• [1]. J. Endell, et al. Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma.Meeting Abstract | 2011 ASCO Annual Meeting I

  [2]. Marc S Raab, et al. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Lancet Haematol. 2020 May;7(5):e381-e394.  [Content Brief]